The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.

Abstract
The single-dose and steady-state pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin and its two major metabolites, M-1 and M-23, were evaluated in patients with renal failure on chronic hemodialysis.

This publication has 0 references indexed in Scilit: